Kerun Biology
Chongqing
About Kerun Biology
Chongqing Kerun Biomedical R&D Co., Ltd. was established in 1997, formerly known as Chongqing Rainwater Group Duotai Biomedical Research Institute, focusing on the research and development of recombinant protein drugs. After nearly two decades of development, the company has established a mature yeast expression technology platform and E. coli expression technology platform, and is currently actively building a mammalian cell expression platform. A drug development system with specifications from options, upstream construction, protein expression, process development, quality control, and registration declarations.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2024)
- Website: biokerun.com
- Phone: 023-68603657
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/kerun-biology-2942875 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.